{
  "metadata": {
    "case_id": 72,
    "model": "GPT-5.1",
    "timestamp": "2025-11-29T18:25:17.829324",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/72_NCT00976573.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/GPT-5.1/72_GPT-5.1.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.identificationModule.secondaryIdInfos",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 6,
      "similarity_matrix": [
        [
          0.32,
          0.28,
          0.4,
          0.62,
          0.68,
          0.74
        ],
        [
          0.7,
          0.7,
          0.4,
          0.35,
          0.7,
          0.6
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 5,
          "score": 0.74,
          "status": "matched",
          "ref_item": {
            "id": "NCI-2011-01968",
            "type": "REGISTRY",
            "domain": "CTRP (Clinical Trials Reporting System)"
          },
          "pred_item": {
            "id": "UG1CA189863",
            "type": "NIH",
            "domain": "National Cancer Institute",
            "link": ""
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 0,
          "score": 0.7,
          "status": "matched",
          "ref_item": {
            "id": "CDR0000654465",
            "type": "REGISTRY",
            "domain": "PDQ (Physician Data Query)"
          },
          "pred_item": {
            "id": "U10CA180821",
            "type": "NIH",
            "domain": "National Cancer Institute",
            "link": ""
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.98,
          0.78
        ],
        [
          0.75,
          0.98
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "label": "Arm I (bevacizumab, paclitaxel, and carboplatin)",
            "type": "EXPERIMENTAL",
            "description": "Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, paclitaxel IV over 60 minutes on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.",
            "interventionNames": [
              "Biological: bevacizumab",
              "Drug: carboplatin",
              "Drug: paclitaxel"
            ]
          },
          "pred_item": {
            "label": "Carboplatin, paclitaxel, and bevacizumab",
            "type": "ACTIVE_COMPARATOR",
            "description": "Patients with unresectable stage IV melanoma received chemotherapy with carboplatin and paclitaxel in combination with the anti-VEGF monoclonal antibody bevacizumab.",
            "interventionNames": [
              "Carboplatin",
              "Paclitaxel",
              "Bevacizumab"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "label": "Arm II(bevacizumab, paclitaxel, carboplatin, and everolimus)",
            "type": "EXPERIMENTAL",
            "description": "Patients receive bevacizumab, paclitaxel, and carboplatin as in Arm I. Patients also receive everolimus PO QD on 3 days a week. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.",
            "interventionNames": [
              "Biological: bevacizumab",
              "Drug: carboplatin",
              "Drug: everolimus",
              "Drug: paclitaxel"
            ]
          },
          "pred_item": {
            "label": "Carboplatin, paclitaxel, bevacizumab, and everolimus",
            "type": "EXPERIMENTAL",
            "description": "Patients with unresectable stage IV melanoma received the same regimen of carboplatin, paclitaxel, and bevacizumab with the addition of the mTOR inhibitor everolimus.",
            "interventionNames": [
              "Carboplatin",
              "Paclitaxel",
              "Bevacizumab",
              "Everolimus"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 4,
      "pred_count": 4,
      "similarity_matrix": [
        [
          0.4,
          0.6,
          0.95,
          0.7
        ],
        [
          0.98,
          0.82,
          0.8,
          0.5
        ],
        [
          0.3,
          0.65,
          0.65,
          0.96
        ],
        [
          0.7,
          0.94,
          0.7,
          0.55
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 2,
          "score": 0.95,
          "status": "matched",
          "ref_item": {
            "type": "BIOLOGICAL",
            "name": "bevacizumab",
            "description": "Given IV",
            "armGroupLabels": [
              "Arm I (bevacizumab, paclitaxel, and carboplatin)",
              "Arm II(bevacizumab, paclitaxel, carboplatin, and everolimus)"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Bevacizumab",
            "description": "A monoclonal antibody targeting vascular endothelial growth factor (VEGF), used in combination with carboplatin and paclitaxel.",
            "armGroupLabels": [
              "Carboplatin, paclitaxel, and bevacizumab",
              "Carboplatin, paclitaxel, bevacizumab, and everolimus"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 0,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "carboplatin",
            "description": "Given IV",
            "armGroupLabels": [
              "Arm I (bevacizumab, paclitaxel, and carboplatin)",
              "Arm II(bevacizumab, paclitaxel, carboplatin, and everolimus)"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Carboplatin",
            "description": "A platinum-based chemotherapeutic agent used as part of the backbone chemotherapy regimen for advanced melanoma in this trial.",
            "armGroupLabels": [
              "Carboplatin, paclitaxel, and bevacizumab",
              "Carboplatin, paclitaxel, bevacizumab, and everolimus"
            ]
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 3,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "everolimus",
            "description": "Given orally",
            "armGroupLabels": [
              "Arm II(bevacizumab, paclitaxel, carboplatin, and everolimus)"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Everolimus",
            "description": "An mTOR inhibitor added to carboplatin, paclitaxel, and bevacizumab in the experimental arm of the trial.",
            "armGroupLabels": [
              "Carboplatin, paclitaxel, bevacizumab, and everolimus"
            ]
          }
        },
        {
          "ref_idx": 3,
          "pred_idx": 1,
          "score": 0.94,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "paclitaxel",
            "description": "Given IV",
            "armGroupLabels": [
              "Arm I (bevacizumab, paclitaxel, and carboplatin)",
              "Arm II(bevacizumab, paclitaxel, carboplatin, and everolimus)"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Paclitaxel",
            "description": "A taxane chemotherapeutic agent combined with carboplatin for treatment of advanced melanoma in this study.",
            "armGroupLabels": [
              "Carboplatin, paclitaxel, and bevacizumab",
              "Carboplatin, paclitaxel, bevacizumab, and everolimus"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.93,
          0.55
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.93,
          "status": "matched",
          "ref_item": {
            "measure": "Progression-free Survival",
            "description": "The primary endpoint is progression-free survival (PFS) defined as the time from randomization to documentation of disease progression or death without documentation of progression. The distribution of PFS times will be estimated using the Kaplan-Meier method. Progression is defined using the RECIST Criteria as at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum of diameters recorded on study (this includes the baseline sum if that is the smallest on study) or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm of target lesions, or the appearance of one or more new lesions, unequivocal progression of existing non-target lesions, although unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.",
            "timeFrame": "Time from randomization to documentation of disease progression or death without documentation of progression;Up to 5 years"
          },
          "pred_item": {
            "measure": "Progression-free survival (PFS)",
            "description": "Time from study enrollment to disease progression or death, compared between patients with and without detectable cell-free DNA BRAFV600E/K mutations, particularly among those with BRAFV600E/K mutations in tumor tissue.",
            "timeFrame": "From enrollment through up to 43 months of follow-up"
          }
        }
      ]
    }
  ]
}